Dr. Ting is the CSO for Kiji Therapeutics, which is developing state-of-the-art off-the-shelf engineered cell therapies for life-threatening diseases. He was recently the Chief Commercialization Officer for ISCT and now serves on the Cell Therapy Advisory group for ARM. Prior to joining Kiji Therapeutics, he served as Program Leader in Oncology Cell Therapy Innovation at Takeda. Dr. Ting was the CSO for Bone Therapeutics and also served as Vice President of Regenerative Medicine and Head of Cardiopulmonary Programs for Athersys.